Status:
COMPLETED
NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
Lead Sponsor:
Merz Pharmaceuticals GmbH
Conditions:
Glabellar Frown Lines
Eligibility:
FEMALE
18-50 years
Phase:
PHASE3
Brief Summary
NT 201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), is a Botulinum toxin type A preparation free of complexing proteins (150 kiloDalton). Injected into the muscle, NT201 causes a reversibl...
Eligibility Criteria
Inclusion
- Main
- • Moderate to severe glabellar frown lines at maximum frown (severity score of 2 or 3 on a 4-point facial wrinkle scale) as assessed by the investigator's rating: 0 = 'none', 1 = 'mild', 2 = 'moderate', 3 = 'severe'.
- Main
Exclusion
- Marked facial asymmetry.
- Ptosis of eyelid and/or eyebrow.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
381 Patients enrolled
Trial Details
Trial ID
NCT00777803
Start Date
November 1 2008
End Date
May 1 2009
Last Update
March 8 2012
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Baden, Austria
2
Krems, Austria
3
Salzburg, Austria
4
Vienna, Austria